Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
69 hedge funds and large institutions have $106M invested in Strongbridge Biopharma plc. in 2020 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 6 closing their positions.
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
116% more capital invested
Capital invested by funds: $48.8M → $106M (+$56.8M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
25% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 20
15% more funds holding
Funds holding: 60 → 69 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.34M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$1.07M |
| 3 |
Renaissance Technologies
New York
|
+$870K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$787K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$555K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$588K |
| 2 |
JP Morgan Chase
New York
|
-$496K |
| 3 |
D.E. Shaw & Co
New York
|
-$460K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$364K |
| 5 |
BlackRock
New York
|
-$345K |
SBBP Hedge Fund Activity: Q2 2020 in Review
69 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q2 2020, worth a combined $106M — up 116% from $48.8M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new SBBP positions and 6 closed out — a net gain of 9 holders — while 25 added to existing stakes and 20 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.34M. The largest seller was Hudson Bay Capital Management, cutting an estimated $588K.
- 69 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q2 2020, up from 60 in Q1 2020.
- Funds reported $106M of Strongbridge Biopharma plc. stock for Q2 2020, up 116% quarter-over-quarter.
- 15 funds opened new Strongbridge Biopharma plc. positions in Q2 2020 and 6 closed out, a net change of +9 holders.
- The largest Strongbridge Biopharma plc. buyer in Q2 2020 was Morgan Stanley, an estimated $3.34M added.
- The largest Strongbridge Biopharma plc. seller in Q2 2020 was Hudson Bay Capital Management, an estimated $588K sold.
Based on aggregated 13F filings for Q2 2020.